Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Affiliation country
Publication year range
2.
Acta Haematol ; 136(3): 167-73, 2016.
Article in English | MEDLINE | ID: mdl-27537981

ABSTRACT

This study focuses on the incidence, treatment, and survival of de novo acute leukemia in a 25-year perspective in western Sweden and Estonia. At the beginning of our study, Estonia was a part of the Eastern bloc with planned economy, but since 1991 it is a member of the European Union and transforming into a market economy. Survival rates have steadily increased in both countries. However, a gap between their survival curves remains. Based on our data, it is difficult to explain the big difference in the 5-year relative survival in favor of western Sweden (55 vs. 22%). In Germany, there was a big difference in overall cancer survival between East and West Germany after the fall of the iron curtain, but today no difference is seen. Differences in survival are probably due to a higher proportion of intense chemotherapy regimens and a higher rate of hematopoietic stem cell transplantations in Sweden. Other important factors might be better supportive care and diagnostics as well as better adjuvant therapy. Better staff training and conditions in wards are also factors that might play an essential role.


Subject(s)
Leukemia/mortality , Acute Disease , Adolescent , Adult , Disease-Free Survival , Estonia/epidemiology , Female , Hematopoietic Stem Cell Transplantation , Humans , Leukemia/diagnosis , Leukemia/therapy , Male , Middle Aged , Prospective Studies , Retrospective Studies , Socioeconomic Factors , Survival Rate , Sweden/epidemiology
3.
Curr Stem Cell Res Ther ; 10(3): 271-82, 2015.
Article in English | MEDLINE | ID: mdl-25429700

ABSTRACT

Despite the numerous recent advances made in conventional anticancer therapies, metastasis and recurrence still remain the major problems in cancer management. The current treatment modalities kill the bulk of the tumor, leaving cancer stem cells behind and therefore, the agents specifically targeting this cancer initiating cell population may have important clinical implications. In this review article, the data about the inhibitory action of flavonoids, both natural as well as their synthetic derivatives, on the self-renewal capacity and survival of cancer stem cells of different origins are compiled and analyzed. These data indicate that several plant secondary metabolites, including soy isoflavone genistein, green tea catechins and a widely distributed flavonol quercetin, have the potential to suppress the stemness markers and properties, traits of the epithelial-to-mesenchymal transition and migratory characteristics, being also able to sensitize these cells to the standard chemotherapeutic drugs. These polyphenolic compounds act through multiple signal transduction pathways, providing thus the maximal therapeutic response and offering some promise to be included in the future cancer treatment schemes in combination with the conventional therapies. Such approach may give an important contribution to the shift of cancer management from palliative to curative mode, likely leading to the disease-free survival. Thus, flavonoids can serve as attractive candidates for novel anticancer agents by eliminating the roots of cancer.


Subject(s)
Antineoplastic Agents/therapeutic use , Flavonoids/therapeutic use , Neoplasms/drug therapy , Neoplastic Stem Cells/drug effects , Animals , Humans , Neoplastic Stem Cells/pathology
SELECTION OF CITATIONS
SEARCH DETAIL